glp-1 advertising policy news GLP-1s have had positive life changing effects for many Americans, there's no doubt about that. But is it a good thing that we're seemingly bombarded with ads for them in recent years? 🚨 FDA UPDATE — April

This personalization capacity supports better adherence and adverse-effect management compared to one-size-fits-all branded protocols

GLP-1 medications are not FDA-approved treatments for ADHD, and large randomized trials specifically targeting ADHD symptoms are still limited

A host-targeting signal in virulence proteins reveals a secretome in malarial infection

The most clinically significant comparative finding came from the SURMOUNT-5 head-to-head trial in 2024, the first direct comparison between two FDA-approved weight loss medications

We explain the molecular mechanisms of these medications and their interactions with other neurotransmitter receptors